What is the best management strategy for an 87-year-old female patient with hypertension, impaired renal function, and currently taking amlodipine 10mg once daily?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 15, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Management of Hypertension in an 87-Year-Old Female with Renal Impairment

For an 87-year-old female with hypertension (146/88 mmHg), impaired renal function (Cr 1.72), and currently on amlodipine 10mg daily, the optimal approach is to add an angiotensin receptor blocker (ARB) while maintaining a more lenient blood pressure target of <140/90 mmHg appropriate for her advanced age. 1

Assessment of Current Situation

  • Current BP: 146/88 mmHg - slightly above target for elderly patients
  • Age: 87 years - falls into the very elderly category (≥85 years)
  • Renal function: Impaired (Cr 1.72) - indicates moderate renal dysfunction
  • Current medication: Amlodipine 10mg daily (maximum recommended dose)

Blood Pressure Targets for Elderly Patients

  • For patients ≥85 years old, the European Society of Cardiology recommends a more lenient target of <140/90 mmHg 1
  • Aggressive BP lowering in elderly patients increases risks of:
    • Orthostatic hypotension
    • Falls
    • Adverse medication effects

Medication Management Recommendations

  1. Maintain amlodipine 10mg daily

    • Amlodipine is effective and safe in patients with renal dysfunction 2, 3
    • No dosage adjustment is necessary for amlodipine in renal impairment 3
  2. Add an ARB as second-line agent

    • The American College of Cardiology suggests using ARBs in combination with calcium channel blockers for patients with chronic kidney disease 1
    • Start with a low dose and titrate based on BP response and renal function
  3. Avoid certain medications

    • Avoid non-dihydropyridine CCBs (diltiazem, verapamil) due to negative inotropic properties 1
    • Use mineralocorticoid receptor antagonists with caution due to risk of hyperkalemia, especially with creatinine >2.5 mg/dL 4
    • Avoid thiazide diuretics if CrCl <30 mL/min 4

Monitoring Recommendations

  1. Regular BP monitoring

    • Check for orthostatic hypotension by measuring BP supine and after standing for 1 and 3 minutes 1
    • Monitor for symptoms of hypotension (dizziness, falls)
  2. Renal function monitoring

    • Check renal function and electrolytes within 1-2 weeks of adding a new antihypertensive agent
    • Monitor potassium levels, especially if adding an ARB 4
  3. Medication review

    • Assess for polypharmacy and potential drug interactions
    • Consider starting with the lowest effective dose of any new medication due to age-related changes in pharmacokinetics 5

Special Considerations for This Patient

  • Frailty assessment: Evaluate for frailty as it may warrant even less aggressive BP targets 1
  • Renal protection: ARBs provide additional renal protection beyond BP control in patients with kidney disease
  • Loop diuretics: Consider a loop diuretic instead of thiazide if estimated GFR is severely reduced 1

Common Pitfalls to Avoid

  • Overly aggressive BP lowering: Can lead to orthostatic hypotension, falls, and cognitive impairment in elderly patients
  • Rapid medication changes: Make one change at a time and allow adequate time for assessment (7-14 days between titration steps) 5
  • Ignoring orthostatic BP changes: Always check for postural drops in BP in elderly patients
  • Neglecting renal function: Close monitoring is essential when adding medications that affect the renin-angiotensin system

By following this approach, you can achieve better BP control while minimizing risks in this elderly patient with renal impairment.

References

Guideline

Antihypertensive Therapy

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Pharmacokinetics of amlodipine in renal impairment.

European journal of clinical pharmacology, 1989

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.